CN114450283B - 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途 - Google Patents

3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途 Download PDF

Info

Publication number
CN114450283B
CN114450283B CN202080068042.2A CN202080068042A CN114450283B CN 114450283 B CN114450283 B CN 114450283B CN 202080068042 A CN202080068042 A CN 202080068042A CN 114450283 B CN114450283 B CN 114450283B
Authority
CN
China
Prior art keywords
methyl
amino
propyl
thiazole
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080068042.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114450283A (zh
Inventor
J·E·P·戴维森
T·诺瓦克
A·帕克扎尔
A·科奇
J-B·斯塔克
J·B·穆雷
S·贝德福德
M·尚里翁
F·科兰德
P·德索斯
M·P·多兹沃思
P·邓克尔
A·赫纳
Z·马达拉什
A·L·马拉尼奥
M·莫尔纳
M·尼耶格斯
R·J·帕森斯
M·鲁达索娃
A·斯特洛克
M·西格蒂
M·P·蒂马里
P·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Original Assignee
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Furnalis R&d Co ltd, Les Laboratoires Servier SAS filed Critical Furnalis R&d Co ltd
Publication of CN114450283A publication Critical patent/CN114450283A/zh
Application granted granted Critical
Publication of CN114450283B publication Critical patent/CN114450283B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080068042.2A 2019-07-29 2020-07-28 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途 Active CN114450283B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188747.0 2019-07-29
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (2)

Publication Number Publication Date
CN114450283A CN114450283A (zh) 2022-05-06
CN114450283B true CN114450283B (zh) 2024-05-07

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080068042.2A Active CN114450283B (zh) 2019-07-29 2020-07-28 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途

Country Status (24)

Country Link
US (1) US20220289734A1 (enExample)
EP (1) EP4003988A1 (enExample)
JP (1) JP7646626B2 (enExample)
KR (1) KR20220042182A (enExample)
CN (1) CN114450283B (enExample)
AR (1) AR119493A1 (enExample)
AU (1) AU2020322072A1 (enExample)
BR (1) BR112022001330A2 (enExample)
CA (1) CA3148502A1 (enExample)
CL (1) CL2021003594A1 (enExample)
CO (1) CO2022000700A2 (enExample)
CR (1) CR20220014A (enExample)
DO (1) DOP2022000015A (enExample)
GE (2) GEAP202415866A (enExample)
IL (1) IL289932B2 (enExample)
JO (1) JOP20220006A1 (enExample)
MX (1) MX2022001161A (enExample)
PE (1) PE20220704A1 (enExample)
PH (1) PH12022550018A1 (enExample)
PY (1) PY2039849A (enExample)
SA (1) SA522431498B1 (enExample)
TW (1) TWI900486B (enExample)
UY (1) UY38809A (enExample)
WO (1) WO2021018857A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021386367A1 (en) * 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
JP2024505562A (ja) * 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
CN101945867A (zh) * 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
CN107614499A (zh) * 2015-05-29 2018-01-19 帝人制药株式会社 吡啶并［3，4‑d］嘧啶衍生物及其药学上可允许的盐

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
CN101945867A (zh) * 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
CN107614499A (zh) * 2015-05-29 2018-01-19 帝人制药株式会社 吡啶并［3，4‑d］嘧啶衍生物及其药学上可允许的盐

Also Published As

Publication number Publication date
EP4003988A1 (en) 2022-06-01
KR20220042182A (ko) 2022-04-04
CR20220014A (es) 2022-03-02
SA522431498B1 (ar) 2025-04-13
TW202118761A (zh) 2021-05-16
CL2021003594A1 (es) 2022-11-18
US20220289734A1 (en) 2022-09-15
DOP2022000015A (es) 2022-05-15
WO2021018857A1 (en) 2021-02-04
BR112022001330A2 (pt) 2022-05-17
JP2022542937A (ja) 2022-10-07
UY38809A (es) 2021-02-26
AU2020322072A1 (en) 2022-02-10
IL289932A (en) 2022-03-01
CA3148502A1 (en) 2021-02-04
CO2022000700A2 (es) 2022-02-07
MX2022001161A (es) 2022-02-22
IL289932B1 (en) 2025-10-01
CN114450283A (zh) 2022-05-06
GEP20247670B (en) 2024-09-25
JOP20220006A1 (ar) 2023-01-30
GEAP202415866A (en) 2024-06-10
NZ784583A (en) 2025-02-28
IL289932B2 (en) 2026-02-01
PE20220704A1 (es) 2022-05-04
PY2039849A (es) 2021-05-06
PH12022550018A1 (en) 2022-10-17
TWI900486B (zh) 2025-10-11
AR119493A1 (es) 2021-12-22
JP7646626B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
CN114450283B (zh) 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途
CN114450284B (zh) 作为bcl-xl蛋白抑制剂的6,7-二氢-5h-吡啶并[2,3-c]哒嗪衍生物
CN110256427B (zh) 2-(吗啉-4-基)-1,7-萘啶
US9688680B2 (en) Compositions useful for treating disorders related to kit
IL311187A (en) Compressed ring compounds
CN105228997A (zh) Carm1抑制剂及其用途
RU2830186C2 (ru) 3,6-диаминопиридазин-3-ильные производные, содержащие их фармацевтические композиции и их применение в качестве проапоптотических средств
HK40068269A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
RU2832191C2 (ru) 6,7-дигидро-5h-пиридо[2,3-c]пиридазиновые производные и родственные соединения в качестве ингибиторов белков bclxl и проапоптотических средств для лечения злокачественных новообразований
HK40068269B (zh) 3，6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途
HK40074219A (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
OA20487A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents.
EA046336B1 (ru) 3,6-диаминопиридазин-3-ильные производные, содержащие их фармацевтические композиции и их применение в качестве проапоптотических средств
EA052683B1 (ru) 6,7-ДИГИДРО-5H-ПИРИДО[2,3-c]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BCL-XL И ПРОАПОПТОТИЧЕСКИХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
HK40013793B (en) 2-(morpholin-4-yl)-1,7-naphthyridines
HK40013793A (en) 2-(morpholin-4-yl)-1,7-naphthyridines
HK40014466B (en) 2-(morpholin-4-yl)-1,7-naphthyridines
HK40014466A (en) 2-(morpholin-4-yl)-1,7-naphthyridines
HK40074798A (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
HK40074798B (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
HK1233262A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068269

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant